This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

NCT04254471 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

313

Enrollment

INDUSTRY

Sponsor class

Conditions

Extensive-stage Small Cell Lung Cancer

Interventions

DRUG: AL3810
DRUG: carboplatin + etoposide
DRUG: Placebo

Sponsor

Haihe Biopharma Co., Ltd.